Shares of Vaccinex Inc. fell to an all-time low on Sept. 22 after top-line results of the phase II trial, Signal, found its SEMA4D inhibitor, pepinemab, failed to improve measures of cognition in people with early manifest Huntington's disease following 18 months of treatment.